Innovations in cancer therapy include Antares Therapeutics’ $177 million raise following its spinout from Scorpion Therapeutics and Nagoya University’s development of next-generation CAR-T cells targeting solid tumor antigen Eva1. Patient-derived xenograft (PDX) models continue to gain importance as preclinical platforms enhancing personalized medicine by better recapitulating tumor heterogeneity and treatment responses.